Paul, Carle

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

Griffiths, C. E. M., Reich, K., Lebwohl, M., van de Kerkhof, P., Paul, C., Menter, A., Cameron, G. S., Erickson, J., Zhang, L., Secrest, R. J., et al. (2015) · The Lancet

Psoriasis: Treatment and PathogenesisDermatology and Skin Diseases

Cited by 834

ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children

Wollenberg, A., Christen‐Zäch, S., Taieb, A., Paul, C., Thyssen, J. P., de Bruin‐Weller, M., Vestergaard, C., Seneschal, J., Werfel, T., Cork, M. J., et al. (2020) · Journal of the European Academy of Dermatology and Venereology

Dermatology and Skin DiseasesContact Dermatitis and Allergies

Cited by 493

Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials

Kimball, A. B., Jemec, G. B. E., Alavi, A., Reguiai, Z., Gottlieb, A. B., Bechara, F. G., Paul, C., Giamarellos Bourboulis, E. J., Villani, A. P., Schwinn, A., et al. (2023) · The Lancet

Hidradenitis Suppurativa and TreatmentsAutoimmune and Inflammatory Disorders

Cited by 343

Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis

Ständer, S., Yosipovitch, G., Legat, F. J., Lacour, J.-P., Paul, C., Narbutt, J., Bieber, T., Misery, L., Wollenberg, A., Reich, A., et al. (2020) · New England Journal of Medicine

Dermatology and Skin DiseasesPsoriasis: Treatment and Pathogenesis

Cited by 281

Defects of filaggrin-like proteins in both lesional and nonlesional atopic skin

Pellerin, L., Henry, J., Hsu, C.-Y., Balica, S., Jean-Decoster, C., Méchin, M.-C., Hansmann, B., Rodriguez, E., Weindinger, S., Schmitt, A.-M., et al. (2013) · Journal of Allergy and Clinical Immunology

Dermatology and Skin DiseasesContact Dermatitis and Allergies

Cited by 239

Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial

Prey, S., Ezzedine, K., Doussau, A., Grandoulier, A.-S., Barcat, D., Chatelus, E., Diot, E., Durant, C., Hachulla, E., de Korwin-Krokowski, J.-D., et al. (2012) · British Journal of Dermatology

Systemic Sclerosis and Related DiseasesConnective tissue disorders research

Cited by 105

Immune modules to guide diagnosis and personalized treatment of inflammatory skin diseases

Seremet, T., Di Domizio, J., Girardin, A., Yatim, A., Jenelten, R., Messina, F., Saidoune, F., Schlapbach, C., Bogiatzi, S., Minisini, F., et al. (2024) · Nature Communications

Dermatology and Skin DiseasesPsoriasis: Treatment and Pathogenesis

Cited by 57

Prevalence and risk factors for fragility fracture in systemic mastocytosis

Degboé, Y., Eischen, M., Nigon, D., Apoil, P.-A., Mailhol, C., Tournier, E., Laurent, C., Hanssens, K., Hermine, O., Paul, C., et al. (2017) · Bone

Mast cells and histamineBone health and osteoporosis research

Cited by 44